Mergers & Acquisitions ·
Liminatus Pharma, Inc. reports that following its merger with InnocsAI LLC, it believes its stockholders' equity…
LIMNWLiminatus Pharma, Inc.
Liminatus Pharma, Inc. reports that following its merger with InnocsAI LLC, it believes its stockholders' equity exceeds $2.5 million, satisfying a key Nasdaq continued listing standard. The company is awaiting a formal compliance determination from the exchange but notes that even if compliant, Nasdaq will monitor ongoing adherence to equity requirements. Failure to demonstrate compliance at the next periodic report could result in future delisting proceedings. Liminatus Pharma operates in the biotechnology industry, focusing on drug discovery and development.